Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.52 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.45 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.45 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | STAT6 | P42226 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31093434 | 1.00 | CTSK (0.52) | CTSKKCNH2SCN2ACXCR2PIN1 | |
| SCHEMBL29008490 | 0.86 | CTSK (0.57) | CTSKKCNH2SCN2ACXCR2PIN1 | |
| SCHEMBL3012997 | 0.83 | HRH1 (0.60) | CTSKSCN2ACXCR2PIN1HRH1 | |
| SCHEMBL27642887 | 0.74 | SCN2A (0.51) | SCN2ACXCR2PIN1HRH1HRH4 | |
| SCHEMBL26467068 | 0.70 | IDO1 (0.49) | CTSKSCN2ACXCR2PIN1HRH1 | |
| SCHEMBL31659840 | 0.70 | IDO1 (0.49) | CTSKSCN2ACXCR2PIN1HRH1 | |
| SCHEMBL7192429 | 0.70 | KIF11 (0.44) | CTSKCXCR2PIN1CTSS | |
| SCHEMBL7667716 | 0.70 | MEN1 (0.55) | PIN1CYP1A2KDM4EMEN1ALDH1A1 | |
| SCHEMBL2562756 | 0.69 | SCN2A (0.47) | SCN2ACXCR2PIN1HRH1HRH4 | |
| SCHEMBL3834391 | 0.69 | TAAR1 (0.47) | CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4673146-A2 | METHODS FOR TREATING OBSESSIVE COMPULSIVE RELATED DISORDERS, TIC DISORDERS AND GLUTAMATE EXCITOTOXICITY RELATED DISORDERS | Biohaven Therapeutics Ltd. (VG) | 2026-01-07 | — | — | EP | claimed |
| WO-2024182465-A2 | METHODS FOR TREATING OBSESSIVE COMPULSIVE RELATED DISORDERS, TIC DISORDERS AND GLUTAMATE EXCITOTOXICITY RELATED DISORDERS | ALCO THERAPEUTICS, LLC (US) | 2024-09-06 | — | — | WO | claimed |
| US-20100204205-A1 | TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE AGENT BY USING THEM IN COMBINATION | OBECURE LTD. (IL) | 2010-08-12 | — | — | US | claimed |
| US-20100160294-A1 | TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE BY USING THEM IN COMBINATION | CYPRESS BIOSCIENCES, INC. | 2010-06-24 | — | — | US | claimed |
| EP-2167096-A1 | IMPROVING THE TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE BY USING THEM IN COMBINATION | Cypress Bioscience, Inc. (US) | 2010-03-31 | — | — | EP | claimed |
| US-20090275562-A1 | TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE BY USING THEM IN COMBINATION | CYPRESS BIOSCIENCES, INC. (US) | 2009-11-05 | — | — | US | claimed |
| WO-2008157094-A1 | IMPROVING THE TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE BY USING THEM IN COMBINATION | CYPRESS BIOSCIENCE, INC. (US) | 2008-12-24 | — | — | WO | claimed |
| US-20100204205-A1 | TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE AGENT BY USING THEM IN COMBINATION | OBECURE LTD. (IL) | 2010-08-12 | — | — | US | disclosed |
| US-20100160294-A1 | TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE BY USING THEM IN COMBINATION | CYPRESS BIOSCIENCES, INC. | 2010-06-24 | — | — | US | disclosed |
| EP-2167096-A1 | IMPROVING THE TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE BY USING THEM IN COMBINATION | Cypress Bioscience, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090275562-A1 | TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE BY USING THEM IN COMBINATION | CYPRESS BIOSCIENCES, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090156581-A1 | Aminergic pharmaceutical compositions and methods | BOARD OF TRUSTREES OF MICHIGAN STATE UNIVERSITY (US) | 2009-06-18 | — | — | US | disclosed |
| WO-2008157094-A1 | IMPROVING THE TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE BY USING THEM IN COMBINATION | CYPRESS BIOSCIENCE, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| EP-1885708-A2 | GPCR MODULATORS | Board of Trustees of Michigan State University (US) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006113557-A2 | GPCR MODULATORS | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275562-A1 | TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE BY USING THEM IN COMBINATION | HTR2A, HTR2C, HTR3A | CTSK 1826/4885KCNH2 795/4885SCN2A 193/4885 |
| US-20100160294-A1 | TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE BY USING THEM IN COMBINATION | HTR2A, HTR3A, HTR2C | CTSK 2038/4885KCNH2 875/4885SCN2A 206/4885 |
| US-20100204205-A1 | TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE AGENT BY USING THEM IN COMBINATION | HTR2A, HTR3A, HTR2C | CTSK 889/4885KCNH2 824/4885SCN2A 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.